Makers Laboratories Limited (506919) Fair Value & Analysis
Healthcare · IN · Market cap ₹505M
Fair value as of: Jul 4, 2026
From 24 valuation models · updated today
Share price −2.3% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹112.05 – ₹175.10 · fair‑value band ₹78.90 – ₹131.51 · the ₹151.45 price screens above the ₹105.20 fair value. As of Jul 4, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Makers Laboratories Limited (506919) currently trades at ₹151.45, while our model-based Fair Value estimate is ₹105.20 — implying the stock looks roughly 30.5% overvalued today. We read business quality at 59/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Makers Laboratories Limited generated revenue of ₹468M at a net margin of 2.4%. Revenue declined 20.7% year over year. It earns a return on equity of 2.5%. Net debt stands at ₹45.7M. Fundamentals as of Jul 4, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 4, 2026. TTM = trailing twelve months.
About the company
Makers Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations in India. The company offers products in general health therapeutic segments, including acid regulatory, anthelmintic, anti-allergic, anti-asthmatic, anti-biotic, anti-diabetics, anti-diarrhoeal, anti-emetics and anti-nauseants, anti-fungal, anti?inflammatory, analgesic, anti-spasmodic, anti-malarial, anti-thyroid, cough and cold control, digestives, neurotonic, nutritional supplements, topical anti-biotic/anti-microbial, and other specialties. It also provides diabetic and hypertensive drugs. The company's principal formulation brands comprise Duramol, Artemak-AB, Loroquin, Nimuwin, Coffwin, and Exylin. It serves approximately 1,500 stockiests'; 1,00,000 doctors; and 2,00,000 retailers through a distribution network of 20 consignment agents and 15 super stockiests'. The company was incorporated in 1984 and is based in Mumbai, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Makers Laboratories Limited reported revenue of ₹1.4B in FY2026 versus ₹1.3B in FY2022, a compound +2.7%/yr. Reported net income was ₹23.5M in FY2026, compounding −17.1%/yr from FY2022.
Is 506919 fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Major stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Syncom Formulations (India) Limited 524470 | ₹14.23 | ₹10.20 | -28% |
| Syschem (India) Limited 531173 | ₹40.64 | ₹6.95 | -83% |
| Unjha Formulations Limited 531762 | ₹18.55 | ₹34.60 | +87% |
| Colinz Laboratories Limited 531210 | ₹77.55 | ₹14.60 | -81% |
| Johnson & Johnson, JNJ | 4,128 MXN | 2,401 MXN | -42% |
| UnitedHealth Group UNH | 7,169 MXN | 5,226 MXN | -27% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Makers Laboratories Limited (506919) undervalued?
What is the fair value of 506919?
What is the quality score of 506919?
What is the revenue of Makers Laboratories Limited (506919)?
What is the net profit margin of 506919?
Does Makers Laboratories Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.